Vir Biotechnology Inc (NASDAQ:VIR) shares fell 15% in premarket trade Friday following the company's announcement of a $150 million public stock offering priced at $10 per share.

A promising biotechnology company developed a new approach that might treat a rare disease — but its sole employee didn’t do ...

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease.

What happened? Shares of Vir Biotechnology fell 18.8% in the afternoon session after the company announced, in a company press release, the pricing of an underwritten public offering of 15 million ...

Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10 per share, raising ...

Agricultural biotechnology once found itself in opposition to environmental science. Now it could reduce the impact of food ...

Overview: Quantum computing, AI, and advanced semiconductors could transform data processing and scientific research.Robotics ...

Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. Read more on VIR ...

Asia Pacific leads as pharmaceutical and biotechnology research adoption accelerates drug discovery, preclinical safety testing and bioactive compound development.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE ...